ALFA Finder| Metric | H1 FY27 | H2 FY26 | H1 FY26 |
|---|---|---|---|
| Revenue from operations | 18.3 | 31.8 | 38.4 |
| Other income | 0.1 | -0.3 | 0.4 |
| Total income | 18.5 | 31.5 | 38.8 |
| Profit before exceptional items & tax | 0.6 | 1.5 | 0.8 |
| Profit before tax | 0.6 | 1.5 | 0.8 |
| Net profit | 0.5 | 1.0 | 0.6 |
| Operating margin | 3.2% | 4.8% | 2.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -16.70% |
|---|---|
| Net profit, quarter on quarter | -50.00% |
| Revenue, year on year | -52.30% |
| Operating profit, year on year | +25.00% |
| Operating profit, quarter on quarter | -72.20% |
NSE results filing, NSE: SAROJA. Figures extracted from the filing.
Saroja Pharma Industries India Ltd: key numbers
- Share price
- ₹38.00
- Market cap
- ₹15.28 Cr
- Revenue (annual)
- ₹70.13 Cr
- Net profit (annual)
- ₹1.61 Cr
- P/E (TTM)
- 9.5×Sector 35.1×
- Promoter holding
- 73.02%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Saroja Pharma Industries India Ltd
All →Saroja Pharma Industries India Management Change
Saroja Pharma's statutory auditor, Pravin Chandak & Associates, revised its resignation to be effective 15 November 2026. The auditor cites pre-occupation in other professional assignments as the reason.
Saroja Pharma Industries India Management Change
Saroja Pharma's statutory auditor Pravin Chandak & Associates resigned effective October 26, 2026, citing pre-occupation. The company will appoint new auditors to fill the vacancy.
Saroja Pharma Industries India Management Change
Mr. Ravindra Shivaji Salaskar has resigned as Whole-time Director of Saroja Pharma Industries India Limited, effective October 5, 2026. He continues as the company's CFO.
Saroja Pharma Industries India Annual General Meeting
Saroja Pharma Industries India Limited held its 8th Annual General Meeting on September 30, 2026, through video conferencing to transact business.
Saroja Pharma Industries India Management Change
Saroja Pharma Industries India Limited appointed Mr. Ravindra Shivaji Salaskar as Chief Financial Officer. He currently serves as a Whole-time Director of the company.
Saroja Pharma Industries India Annual General Meeting
Saroja Pharma Industries India Limited has issued a notice for its 8th Annual General Meeting, scheduled to be held on September 30, 2026, through video conferencing.